EXPLAINER: ANKTIVA- The Next Great Longevity Drug?

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.

In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.

CHAPTERS:
00:00 — Introduction: The Blood Test Number Better Than Cholesterol
00:35 — What Is Lymphopenia and Why It Matters
01:50 — Immunosenescence: Why Your T Cells Decline After Age 20
02:30 — The Mortality Data: Three Studies on Lymphopenia
03:20 — Copenhagen Study: 63% Higher All-Cause Mortality
03:50 — Coronary Angiography Study: Hazard Ratio 1.97
04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells
05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer
06:00 — Four Hallmarks of Aging Hit By One Molecule
06:30 — ANKTIVA Explained: The IL-15 Super-Agonist
07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe
08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case
09:00 — The Skeptical Case: Why We Don't Know Yet
10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally
11:30 — Final Take and Closing

KEY TAKEAWAYS:

• Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studies
• IL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancer
• Resistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay young
• ANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatment
• IL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopenia
• Honest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this space

STUDIES & SOURCES MENTIONED:

• Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)
• Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adults
• Bawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patients
• FDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancer

Watch the full video on YouTube: https://youtu.be/220KHIdFCwg

📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/
📰 Substack newsletter: https://robertlufkinmd.substack.com
🌐 Website: https://robertlufkinmd.com

Enjoyed this episode? Reviews on Apple Podcasts are the #1 way to help the show grow. Tap here to leave one in 30 seconds: https://podcasts.apple.com/us/podcast/health-longevity-secrets/id1585563694

⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!

New episodes every other Tuesday. Subscribe so you don't miss one.

Continue this conversation on Substack: https://robertlufkinmd.substack.com
Lies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/

Web: https://www.robertlufkinmd.com
YouTube: https://www.youtube.com/robertlufkinmd
X: https://x.com/robertlufkinmd
Instagram: https://www.instagram.com/robertlufkinmd/
TikTok: https://www.tiktok.com/@robertlufkin
LinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Transcript

The Overlooked Blood Test Number

SPEAKER_00 0:00

There's a single number on your routine blood test that predicts your risk of dying from cancer, from heart disease, from infection, from almost everything, better than your cholesterol does. Most doctors glance right past it. And here's what's wild. There's now an FDA-approved drug that, for the first time, may let us actually move that number in the right direction. I'm Dr. Robert Lufkin. Today we're talking about lymphopenia, IL15, and a drug called Anctiva and whether it might quietly turn out to be one of the most important longevity drugs of the decade.

Lymphopenia Basics And Why It Matters

SPEAKER_00 0:39

Part one. Quick vocabulary because words matter. Leukopenia means low total white blood cells. Lymphopenia is more specific. It means low lymphocytes. That's the family that includes your T cells, your B cells, and your natural killer cells or NK cells. These are the immune cells doing the most important long-term jobs in your body. Every single day they're patrolling for cancer cells, killing virus-infected cells, and this is the most the part that most people don't appreciate, clearing out senescent cells, the zombie cells that accumulate with age and pump out inflammatory signals that drive almost every chronic disease. Now, here's the problem. Starting in your 20s, your thymus, that's the organ that trains the T cells, begins to shrink. By the time you're 60, it's mostly fat. Your bone marrow gets less productive. Chronic low-grade inflammation, what researchers call inflammaging, exhausts the cells that you do have. The net result? Lymphocyte counts drift down as you age, and the cells that are left don't work as well. Immunologists call this immunosinescence. And normal absolute lymphocyte count is roughly 1,000 to 3,000 per microliter. Below about 1500, that's relative lymphopenia. Below 1,000, that's severe. And it turns out where you sit on that scale tells us a lot more about how long you're going to live.

The Mortality Data Behind Low Lymphocytes

SPEAKER_00 2:28

Part two, the mortality data. Three big studies. Pay attention to the numbers. Study one, JAMA Open Network, 2019. Researchers looked at over 31,000 American adults in the NHANES database. People with severe lymphopenia had a hazard ratio of 1.8 for dying from any cause, almost double. And when they combined lymphopenia with two other cheap blood markers, red blood cell distribution width and C-reactive protein, the 10-year mortality ranged from under 4% in the healthiest group to 62% in the worst. 62% from a routine blood draw. Okay, study two. The Copenhagen general population study, over 108,000 people followed for years. Lymphopenia was associated with a 63% increase in all cause mortality, plus a 1.5 to nearly three-fold higher risk of dying from cancer, cardiovascular disease, respiratory disease, and infection. Independent of age, independent of smoking, independent of cholesterol. Study three. Over 15,000 patients followed for eight years after coronary angiography. Severe lymphopenia roughly doubled the long term long-term mortality, a hazard ratio of 1.97. Three different populations, same signal. Lymphopenia is one of the strongest, cheapest, most reproducible predictors of death that we have. Which raises the obvious question if low lymphocytes accelerate dying, what happens if we can safely raise them?

IL-15 And The Immune System Gas Pedal

SPEAKER_00 4:23

Part three. Enter IL-15. To answer that, you need to know about a molecule called interleukin-15 or IL-15 for short. IL-15 is a cytokine, a signaling protein, and its job is essentially to tell your immune system grow more, work harder. Specifically, IL-15 expands and activates the exact cells you lose with age. The NK cells, the C D8 plus killer T cells, and memory T cells. And here's the elegant part. Unlike its cousin IL2, which also expands regulatory T cells, the breaks on the immune system, IL15 only hits the gas. It builds the killer side without building the suppressor side. Two more things you should know about IL-15. First, it's also a myokine. Your skeletal muscle releases it when you contract it. Second, NK cells, the cells that IL-15 expands are the main natural senolytic in your body. They are the cleanup crew for senescent zombie cells. As NK function falls with age, zombie cells accumulate and aging accelerates. So IL-15 sits at the intersection of at least four hallmarks of aging at once immunosinescence, senescent cell accumulation, chronic inflammation, and sarcopenia, or age-related muscle loss. Four hallmarks, one molecule. That's why people are paying attention.

Anctiva And The New FDA Approval

SPEAKER_00 6:19

Part four, Anctiva. This brings us to Anctiva. The generic name is nogopendicin alpha inbaquescip, which is an IL-15 superagonist, a mutated, more potent version of IL-15 bound to its own receptor on an antibody scaffold, which makes it last longer in the body and activates NK and CD8 cells much more strongly than natural IL-15 ever could. Now, the FDA approved Anctiva in April of 2024 combined with BCG for a serious form of bladder cancer called BCG unresponsive non-muscle invasive bladder cancer. In patients who were essentially out of options, Anctiva produced durable, complete responses. It's the first IL-15 agonist ever approved by the FDA. And the early data outside of bladder cancer in HIV reservoir reduction in other solid tumors looks genuinely promising. And then just recently at the American Urological Association meeting of a couple weeks ago, Dr. Patrick Soon Shaong, the physician scientist who developed Anctiva, gave an hour-long talk explicitly reframing the drug, not just as a cancer drug, as a treatment for lymphopenia itself. To quote, a comprehensive review of the potential of IL-15 as we have begun to understand the consequences of lymphopenia. That is a very big shift in framing. He is essentially saying the cancer indication is the beach head. The real prize is aging. Part five.

Longevity Potential And Real Risks

SPEAKER_00 8:21

So is Anctiva the next great longevity drug? Let me steel man both sides. Well, the bullish case, it it hits multiple hallmarks of aging, as we as we discussed. It's already FDA approved, so safety, manufacturing, and the regulatory pathway are established, and that is enormous. There's a clean biomarker, lymphocyte count, and NK function that makes longevity trials tractable. And mechanistically, it doesn't overlap with rapamycin, metformin, or GLP1 agonists, which means it could stack on top of them. Now let's hear the other side, the skeptical case. And you have to hear this. One, always association is not causation. Lymphopenia might be a marker of sick bone marrow or chronic underlying disease, but not a cause of it. Pharmacologically pushing the number up might not push survival up. Two, there's no human longevity randomized trial. Zero. All current data are in cancer. Three, Anctiva today is delivered into the bladder and is extremely expensive. Systemic dosing in healthy aging adults is still unproven. Four, immune activation is not free. Cytokine release, autoimmune immunity, and the theoretical risk of feeding microcancers you don't know about yet, all of that we need more long-term data on. Five, more isn't always better. Some data suggest a J-shaped curve. You know, very high lymphocyte counts are are also perhaps bad. That's there's a maybe a Goldilocks zone. So my honest take, IL-15 agonism is one of the most exciting longevity hypotheses on the table right now. But right now, it's a hypothesis with an FDA approval. Not necessarily a longevity drug with longevity evidence. Watch this space because that may change fast.

What You Can Do Today

SPEAKER_00 10:24

Part six, what you could do today. One, know your number. The next time you get a CBC, look at the absolute lymphocyte count. Track it across years. And if it's drifting below 1500, that's a conversation to have with your doctor. Two, raise IL-15 the freeway. Resistance training is the single strongest known endogenous IL-15 stimulus. Lift heavy things, add adequate protein, protect your sleep. Lymphocide counts are remarkably sleep-sensitive and aggressively treat chronic infections, gum disease, and visceral fat, because all three suppress lymphocytes. Three, maybe don't chase Anctiva off-label. Wait for the longevity-specific trials, which, based on what Dr. Soon Chang said, is is now saying publicly are coming or are beginning to be underway. Tell me in the comments if the longevity trial for an IL-15 agonist drug came back positive, would you take it? Yes or no? I'm Dr. Robert Lufkin, and we'll see you in the next one.

Subscribe Review And Medical Disclaimer

SPEAKER_00 11:42

If you are enjoying this program, please hit that subscribe button or even better, leave a review. Your support makes it possible for us to create the quality programming that we're continually striving for.

SPEAKER_01 11:56

Can I start? Is it recording?

SPEAKER_00 11:58

It's already recorded.

SPEAKER_01 11:59

Oh sorry. This is for general information and educational purposes only. It is not intended to constitute or substitute for medical advice or counseling. The practice of medicine or the healthcare diagnostics. Or the creation of a specific patient on a clinical relationship. The use of this information is a bit on the finding to be on the value, please hit that like button and subscribe to support the work that we do on the channel. And we've taken your suggestions and the mic very seriously, so please let us know what you're like to see in the channel. Thanks for watching, and we hope to see you next time.

SPEAKER_00 12:54

I think you have to do it.

SPEAKER_01 12:56

You need to use the recording.